Literature DB >> 12548166

Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays.

Andrew N Young1, Paulo G de Oliveira Salles, So Dug Lim, Cynthia Cohen, John A Petros, Fray F Marshall, Andrew S Neish, Mahul B Amin.   

Abstract

The common histopathologic subtypes of renal epithelial neoplasms include conventional, or clear cell, renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, and renal oncocytoma. These subtypes differ clinically and pathologically, making accurate classification important. However, this differential diagnosis can be challenging because of overlapping morphology, suggesting a potential utility for ancillary immunohistochemical markers. We used cDNA microarrays to identify candidate markers for distinguishing renal tumor subtypes. In this report we validated differential expression of three candidate markers, beta defensin-1, parvalbumin, and vimentin, and evaluated the use of this immunohistochemical panel as a potential diagnostic tool. Consistent with our cDNA microarray data, chromophobe RCCs and oncocytomas exhibited similar expression profiles: 8 of 8 examples of each subtype were immunohistochemically positive for beta defensin-1 and parvalbumin and negative for vimentin (sensitivity 100%, specificity 100%); 4 of 7 papillary RCCs were positive for beta defensin-1, parvalbumin, and vimentin (sensitivity 57%, specificity 97%); and 22 of 23 conventional RCCs were negative for beta defensin-1, parvalbumin, or both markers (sensitivity 96%, specificity 96%) as well as positive for vimentin (sensitivity 83%). The immunohistochemical panel distinguished renal tumor subtypes with greater specificity than any marker used alone. This work demonstrates that a useful panel of immunohistochemical markers can be derived from differential gene expression profiles determined using cDNA microarrays.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548166     DOI: 10.1097/00000478-200302000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

Review 1.  What can molecular pathology contribute to the management of renal cell carcinoma?

Authors:  Grant D Stewart; Fiach C O'Mahony; Thomas Powles; Antony C P Riddick; David J Harrison; Dana Faratian
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

2.  Molecular classification of renal tumors by gene expression profiling.

Authors:  Audrey N Schuetz; Qiqin Yin-Goen; Mahul B Amin; Carlos S Moreno; Cynthia Cohen; Christopher D Hornsby; Wen Li Yang; John A Petros; Muta M Issa; John G Pattaras; Kenneth Ogan; Fray F Marshall; Andrew N Young
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

3.  Utilization of plant-derived recombinant human β-defensins (hBD-1 and hBD-2) for averting salmonellosis.

Authors:  Sunita Patro; Soumitra Maiti; Santosh Kumar Panda; Nrisingha Dey
Journal:  Transgenic Res       Date:  2014-11-23       Impact factor: 2.788

4.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05

5.  Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.

Authors:  Adeboye O Osunkoya; Qiqin Yin-Goen; John H Phan; Richard A Moffitt; Todd H Stokes; May D Wang; Andrew N Young
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

6.  Decreased urinary beta-defensin-1 expression as a biomarker of response to arsenic.

Authors:  Christine M Hegedus; Christine F Skibola; Marcella Warner; Danica R Skibola; David Alexander; Sophia Lim; Nygerma L Dangleben; Luoping Zhang; Michael Clark; Ruth M Pfeiffer; Craig Steinmaus; Allan H Smith; Martyn T Smith; Lee E Moore
Journal:  Toxicol Sci       Date:  2008-05-28       Impact factor: 4.849

7.  Effective control of Salmonella infections by employing combinations of recombinant antimicrobial human β-defensins hBD-1 and hBD-2.

Authors:  Soumitra Maiti; Sunita Patro; Sukumar Purohit; Sumeet Jain; Shantibhusan Senapati; Nrisingha Dey
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

8.  Identification and characterization of renal cell carcinoma gene markers.

Authors:  Gul S Dalgin; Dustin T Holloway; Louis S Liou; Charles DeLisi
Journal:  Cancer Inform       Date:  2007-02-09

9.  High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas.

Authors:  Maria V Yusenko; Roland P Kuiper; Tamas Boethe; Börje Ljungberg; Ad Geurts van Kessel; Gyula Kovacs
Journal:  BMC Cancer       Date:  2009-05-18       Impact factor: 4.430

10.  Manual annotation and analysis of the defensin gene cluster in the C57BL/6J mouse reference genome.

Authors:  Clara Amid; Linda M Rehaume; Kelly L Brown; James G R Gilbert; Gordon Dougan; Robert E W Hancock; Jennifer L Harrow
Journal:  BMC Genomics       Date:  2009-12-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.